Organon & Co. (NYSE:OGN) outlined a 2026 outlook broadly in line with 2025 results, highlighting efforts to stabilize revenue, hold profitability steady, and continue deleveraging, while also fielding ...

Organon & Co. (NYSE:OGN) Q4 2025 Earnings Call Transcript February 12, 2026 Organon & Co. misses on earnings expectations.

An update from Organon ( (OGN) ) is now available.

Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on ...

To prioritize balance sheet repair, Organon reduced its dividend payout ratio to free up more cash for debt reduction. It also discontinued certain early-stage clinical programs and tightened R&D ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Revenue came in at $1.51 billion, below the consensus estimate of $1.54 billion and down 5% from the same period last year. On a constant currency basis, revenue declined 8% year-over-year. Women’s ...

Q4 2025 Management View Joseph Morrissey, Interim CEO & Executive VP and Head of Manufacturing & Supply, stated that "In 2025, Organon delivered $6.2 billion in revenue and $1.9 billion of adjusted ...

Media reports this week suggested that Sun Pharma is in discussions with lenders to arrange financing for the acquisition and has submitted non-binding bids, which could value Organon at over $10 ...